< Back to previous page
Researcher
Ann Gils
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Apr 2013 → 31 Aug 2019
Projects
1 - 10 of 18
- BIOLOPTIM: implementing therapeutic drug monitoring of biologics for psoriasis and hidradenitis suppurativaFrom1 Oct 2018 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Mass cytometry by time-of-flight: next-generation flow cytometry for multiplexed single cell analysisFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- Improving treatment outcomes for patients with chronic inflammatory diseases through identification of predictive biomarkers and therapeutic drug monitoring of new biologicalsFrom28 Aug 2017 → 31 Dec 2021Funding: FWO Strategic Basic Research Grant
- Immunogenicity of biological agents in inflammatory bowel disease and psoriasis: clinical relevance of early detection, characterization and prevention of anti-drug antibodies.From1 Oct 2016 → 30 Sep 2020Funding: FWO Applied Biomedical Research (TBM)
- Implementation of infliximab dosage regimen stratification through generalization/validation of rapid concentration-determining assays and generation of population-based pharmacokinetic/pharmacodynamic modelsFrom1 Oct 2015 → 30 Sep 2017Funding: IOF - Industrial Research Fund
- Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseasesFrom1 Sep 2014 → 7 May 2019Funding: BOF - Doctoral projects
- Development, validation and clinical application of assas in order to perform blood concentration measurements of biological.From1 Oct 2013 → 31 Dec 2018Funding: IWT personal funding - strategic basic research grants
- Translating therapeutic drug monitoring of biopharmaceuticals into individualised care of inflammatory bowel disease patients through pharmacometric modelling en farmaco-economic evaluation.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
- Development and validation of rapid assays to quantify infliximab trough levels and antibodies towards infliximab.From17 Sep 2012 → 31 Dec 2017Funding: IWT personal funding - strategic basic research grants
- Optimizing treatment of IBD patients with anti-TNFalpha biopharmaceuticals via pharmacokinetic monitoring of trough levels and calculating the cost-effectiveness of this trough level based therapy.From1 Jan 2012 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 229
- A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab(2022)
Authors: Ann Gils
Pages: 1549 - 1554 - Optimisation of long-term outcomes in paediatric inflammatory bowel disease patients: role of therapeutic drug monitoring and endoscopic remission.(2020)
Authors: Karen van Hoeve, Séverine Vermeire, Ilse Hoffman, Ann Gils
- Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center(2020)
Authors: Annick Moens, Matthias Lenfant, Gert Van Assche, Séverine Vermeire, Ann Gils, Marc Ferrante
Pages: 628 - 634 - A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis(2020)
Authors: Erwin Dreesen, Wannee Kantasiripitak, Séverine Vermeire, Marc Ferrante, Thomas Bouillon, Ann Gils
Pages: 570 - 580 - Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease(2020)
Authors: Erwin Dreesen, Peter Bossuyt, Séverine Vermeire, Ann Gils
Pages: 637 - + - Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis(2020)
Authors: Nathalie Van den Berghe, Rani Soenen, Ann Gils
Pages: 390 - 397 - Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease Reply(2020)
Authors: Erwin Dreesen, Ann Gils
Pages: 262 - 263 - Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study(2019)
Authors: Bram Verstockt, Ann Gils, Peter Bossuyt, Philippe Van Hootegem, Séverine Vermeire
Pages: 1401 - 1409 - Achieving mucosal healing in inflammatory bowel diseases: which drug concentrations need to be targeted?(2019)
Authors: Nathalie Van den Berghe, Ann Gils
Pages: 945 - 954 - Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study(2019)
Authors: Erwin Dreesen, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
Pages: 1248 - 1256
Patents
1 - 3 of 3
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)